menu
    • menu
    [{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Lilly Asia Ventures","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Series A Financing","leadProduct":"RNA Therapeutic","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Rona Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ Lilly Asia Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Rona Therapeutics \/ Lilly Asia Ventures"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Large molecule","year":"2022","type":"Licensing Agreement","leadProduct":"siRNA Therapeutic","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Preclinical","graph3":"Rona Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ Rona Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Rona Therapeutics \/ Rona Therapeutics"},{"orgOrder":0,"company":"Rona Therapeutics","sponsor":"LongRiver Investments","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"CHINA","productType":"Large molecule","year":"2024","type":"Series A Financing","leadProduct":"RN0191","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Rona Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Rona Therapeutics \/ LongRiver Investments","highestDevelopmentStatusID":"12","companyTruncated":"Rona Therapeutics \/ LongRiver Investments"}]

    Find Clinical Drug Pipeline Developments & Deals by Rona Therapeutics

    Menu

    Rona Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Rona Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rona Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RN0191

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase I

                            Sponsor : LongRiver Investments

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Rona Therapeutics Raises $35M Series A+ to Advance Innovative Metabolic siRNA Pipeline

                            Details : The financing aims to fund the clinical development of the company's first program RN0191, a best-in-class PCSK9 siRNA program, which is being evaluated for treating Hypercholesteremia.

                            Brand Name : RN0191

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 19, 2024

                            Lead Product(s) : RN0191

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase I

                            Sponsor : LongRiver Investments

                            Deal Size : $35.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Rona Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rona Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : siRNA Therapeutic

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Preclinical

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfo...

                            Details : Rona licensed Sanofi’s siRNA platform to enable discovery programs in expanded therapeutic areas including neuro and muscular diseases, for which Sanofi has an exclusive option to acquire neuro and muscular disease candidates for ex-China territories.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            July 25, 2022

                            Lead Product(s) : siRNA Therapeutic

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Preclinical

                            Recipient : Sanofi

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Rona Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Rona Therapeutics

                            China arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : RNA Therapeutic

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Lilly Asia Ventures

                            Deal Size : $33.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Devel...

                            Details : The RNA medicines from Rona Therapeutics are modular and programmable modalities targeting disease areas across metabolic diseases, neurological diseases and ophthalmology diseases via different delivery systems.

                            Brand Name : Undisclosed

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            April 07, 2022

                            Lead Product(s) : RNA Therapeutic

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Lilly Asia Ventures

                            Deal Size : $33.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth